Ocular Therapeutix Clears FDA Pre-NDA Meeting for AXPAXLI in Wet AMD, NDA Submission on Track for Q4 2026
核心洞察
Ocular Therapeutix completed a positive Pre-NDA meeting with the FDA for AXPAXLI (OTX-TKI) in wet age-related macular degeneration (搜索), confirming the planned NDA package.
The NDA will rest on Week 52 efficacy and safety data from the Phase 3 SOL-1 trial, interim safety data from SOL-R, and supporting confirmatory evidence.
Submission remains on track for the fourth quarter of 2026 under the 505(b)(2) pathway, which could shorten FDA review by up to 60 days.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced the successful completion of its Pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (搜索) for AXPAXLI (also known as OTX-TKI), its investigational treatment for wet age-related macular degeneration (搜索) (wet AMD). The company said its expectations for the NDA package remain consistent with prior FDA communications, including the May 2026 Type C Meeting, and that it remains on track to submit the NDA in the fourth quarter of 2026.
"Following our successful Pre-NDA Meeting with the FDA, we are on track for our planned AXPAXLI NDA submission in the fourth quarter of 2026," said Pravin U. Dugel, M.D., Executive Chairman, President and CEO of Ocular Therapeutix. "We are immensely grateful to the FDA for their collaboration throughout this process and will continue to follow their guidance as we advance AXPAXLI through NDA submission, review, and potential approval."
NDA Package Built on SOL-1 and Interim SOL-R Data
Consistent with the FDA Type C Meeting minutes previously communicated by the company, the planned submission will be based on Week 52 efficacy and safety data from the registrational Phase 3 SOL-1 trial, interim safety data from the ongoing Phase 3 SOL-R trial, and supporting confirmatory evidence. The submission will also include subjects who have received multiple AXPAXLI injections in support of the company's application for repeat dosing.
The SOL-1 superiority trial was designed and conducted under a Special Protocol Assessment (SPA) agreement with the FDA and, in February 2026, met its pre-specified primary endpoint with high statistical significance. The SOL program consists of three registrational trials in wet AMD: SOL-1 (NCT06223958), initiated in 2023 under a modified SPA; SOL-R (NCT06495918), which enrolled its first patients in 2024; and SOL-X, an open-label extension with three-year follow-up. The program is seeking to enable more infrequent intravitreal dosing, with a target of one to two injections per year.
Ocular said the September 2026 Pre-NDA Meeting further confirmed alignment with the FDA on the content and format of the planned submission under the 505(b)(2) pathway. That route allows a company to rely in part on prior clinical findings supporting previously approved drugs — in this case, axitinib, AXPAXLI's active ingredient, which has already received regulatory approval for non-ophthalmic indications. According to the company, the 505(b)(2) pathway has the potential to shorten the FDA review timeline by up to 60 days compared with the traditional 505(b)(1) pathway for a new molecular entity. Ocular also remains on schedule to conduct the interim SOL-R safety analysis in the fourth quarter of 2026.
Durability Claims and Competitive Positioning
Dugel framed the SOL-1 dataset as sufficient for immediate clinical use following a potential approval. "That approach has served us well and has brought us to a position where AXPAXLI has the potential to be not only the first TKI to market for wet AMD, if approved, but also the only novel product candidate supported by a positive Phase 3 superiority trial against an approved anti-VEGF," he said. "We believe physicians will have all the data they need from SOL-1 to begin using AXPAXLI immediately following potential approval, due to the unmatched durability and level of sustained disease control observed in SOL-1 that is simply unprecedented in this space."
Investigators have similarly described the candidate as having "unmatched (durability) in the wet AMD space while demonstrating excellent sustained disease control," according to the company. Ocular said commercial readiness is accelerating ahead of a potential 2027 launch.
Hydrogel Platform and Mechanism
AXPAXLI is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small-molecule, multi-target tyrosine kinase (搜索) inhibitor with anti-angiogenic properties. It is being evaluated for wet AMD and diabetic retinal disease, including non-proliferative diabetic retinopathy (搜索) (NPDR). The implant is delivered via a 25G needle with a target release window of 9 to 12 months, and is described as biocompatible and tunable for use across multiple locations in the eye.
The candidate is based on Ocular's ELUTYX (搜索) proprietary bioresorbable hydrogel-based formulation technology, designed for localized sustained release to maximize therapeutic efficacy while minimizing systemic exposure. The same platform underlies the company's FDA-approved commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and for ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older. It also supports OTX-TIC (搜索), a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for open-angle glaucoma (搜索) or ocular hypertension (搜索); Ocular said it is currently evaluating next steps for that program.
Unmet Need in Wet AMD
Wet AMD is a leading cause of severe, irreversible vision loss, affecting approximately 14.8 million individuals globally and 1.8 million in the United States alone. The condition causes vision loss through abnormal new blood vessel growth and hyperpermeability and associated retinal vascularity in the macula, primarily stimulated by local upregulation of vascular endothelial growth factor (搜索) (VEGF). Without prompt and continuous treatment to control this exudative activity, patients develop irreversible vision loss.
Challenges with current therapies include pulsatile, repeated intraocular injections, treatment-related adverse events, and up to 40% patient discontinuation within one year of initiating treatment with continued disease progression. According to the company, these factors together lead to undertreatment and a lack of long-term vision improvement for patients.
Ocular's forward-looking statements note substantial risks and uncertainties, including whether the FDA will accept an NDA for AXPAXLI on the basis of a single pivotal trial, whether the agency will agree with the company's interpretation of the SPA agreements and meeting minutes, whether the NDA will qualify for review under the 505(b)(2) pathway and whether that pathway will provide time savings, and whether the submitted data will be sufficient to support marketing approval in wet AMD.